Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7423008 | 0.85 | RAB9A (0.49) | RAB9ANPC1MAPTSMN1; SMN2GRM2 | |
| SCHEMBL8635430 | 0.75 | AKT1 (0.44) | GRM2 | |
| SCHEMBL2526085 | 0.75 | ALDH1A1 (0.39) | RAB9ANPC1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL7247305 | 0.74 | GRM2 (0.43) | GRM2 | |
| SCHEMBL4398498 | 0.74 | RIPK1 (0.53) | GRM2KMT2AMEN1 | |
| SCHEMBL7385091 | 0.74 | LOXL2 (0.55) | RAB9AMAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3819098 | 0.73 | AKT1 (0.52) | RAB9ANPC1KMT2ALMNAMEN1 | |
| SCHEMBL1010216 | 0.71 | MEP1A (0.50) | GRM2LMNA | |
| SCHEMBL23241902 | 0.71 | MAPT (0.74) | RAB9ANPC1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL23241901 | 0.71 | MAPT (0.74) | RAB9ANPC1MAPTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190747-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20210330671-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2021-10-28 | — | — | US | disclosed |
| US-20200383982-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2020-12-10 | — | — | US | disclosed |
| US-20190262338-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2019-08-29 | — | — | US | disclosed |
| US-20190000845-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2019-01-03 | — | — | US | disclosed |
| US-9937175-B2 | Phenyloxadiazole derivatives as PGDS inhibitors | SANOFI (FR) | 2018-04-10 | — | — | US | disclosed |
| US-20170231990-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI- AVENTIS (FR) | 2017-08-17 | — | — | US | disclosed |
| US-9469627-B2 | Phenyloxadiazole derivatives as PGDS inhibitors | SANOFI (FR) | 2016-10-18 | — | — | US | disclosed |
| US-20120190695-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI (FR) | 2012-07-26 | — | — | US | disclosed |
| US-6228854-B1 | 1-BENZAZEPINE DERIVATIVE ANTICOAGULANTS; STROKE PREVENTION | COR THERAPEUTICS, INC. | 2001-05-08 | — | — | US | disclosed |
| EP-0994894-A1 | SELECTIVE FACTOR Xa INHIBITORS | COR THERAPEUTICS, INC. (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999007731-A1 | SELECTIVE FACTOR Xa INHIBITORS | COR THERAPEUTICS, INC. (US) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000845-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | RAB9A 2523/4885NPC1 1794/4885MAPT 1260/4885 |
| US-20200383982-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | RAB9A 2523/4885NPC1 1794/4885MAPT 1260/4885 |
| US-20190262338-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | RAB9A 2452/4885NPC1 1781/4885MAPT 1333/4885 |
| US-20120190695-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | RAB9A 2523/4885NPC1 1794/4885MAPT 1260/4885 |
| US-20230190747-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | RAB9A 2523/4885NPC1 1794/4885MAPT 1260/4885 |
| US-20210330671-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | RAB9A 2497/4885NPC1 1730/4885MAPT 1249/4885 |
| US-20170231990-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | RAB9A 2523/4885NPC1 1794/4885MAPT 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.